Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics, Inc. (HOWL)
:HOWL
HOWL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $6.89
Previous CloseN/A
Volume113.58K
Average Volume (3M)256.29K
Market Cap
$37.20M
Enterprise Value-$8.08M
Total Cash (Recent Filing)$111.00M
Total Debt (Recent Filing)$37.09M
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 07, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding44,827,160
10 Day Avg. Volume228,793
30 Day Avg. Volume256,291
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)127.27
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.29
Enterprise Value/Ebitda0.12
Forecast
1Y Price Target
$9.25Price Target Upside1014.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Werewolf Therapeutics Appoints Anil Singhal to Board---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsEarly anti-tumor activity was observed in WTX-330 with a confirmed partial response in a metastatic melanoma patient, achieving a 46% reduction in tumor size.
Investment OpportunityWerewolf Therapeutics has a partnership with Jazz Pharmaceuticals and a cash position of $122.8 million, representing an interesting investment opportunity given its enterprise value of $5.3 million.
Bears Say
Financial PerformanceFor 4Q24, Werewolf reported no revenues and higher R&D expenses than estimated, resulting in a greater EPS loss than anticipated.
Revenue ConcernsWerewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.
---
Ownership Overview
27.83%
Insiders
5.22% Mutual Funds
42.46% Other Institutional Investors
18.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HOWL FAQ
What was Werewolf Therapeutics, Inc.’s price range in the past 12 months?
Werewolf Therapeutics, Inc. lowest stock price was $0.59 and its highest was $6.89 in the past 12 months.
What is Werewolf Therapeutics, Inc.’s market cap?
Werewolf Therapeutics, Inc.’s market cap is $37.20M.
When is Werewolf Therapeutics, Inc.’s upcoming earnings report date?
Werewolf Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 14 days.
How were Werewolf Therapeutics, Inc.’s earnings last quarter?
Werewolf Therapeutics, Inc. released its earnings results on Mar 11, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.403 by -$0.057.
Is Werewolf Therapeutics, Inc. overvalued?
According to Wall Street analysts Werewolf Therapeutics, Inc.’s price is currently Undervalued.
Does Werewolf Therapeutics, Inc. pay dividends?
Werewolf Therapeutics, Inc. does not currently pay dividends.
What is Werewolf Therapeutics, Inc.’s EPS estimate?
Werewolf Therapeutics, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Werewolf Therapeutics, Inc. have?
Werewolf Therapeutics, Inc. has 44,827,160 shares outstanding.
What happened to Werewolf Therapeutics, Inc.’s price movement after its last earnings report?
Werewolf Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.403. Following the earnings report the stock price went up 3.279%.
Which hedge fund is a major shareholder of Werewolf Therapeutics, Inc.?
Currently, no hedge funds are holding shares in HOWL
---
Werewolf Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (1014.46% Upside)
$9.25 (1014.46% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.64%
12-Months-Change
Fundamentals
Return on Equity
-76.33%
Trailing 12-Months
Asset Growth
-25.93%
Trailing 12-Months
Company Description
Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
---
HOWL Stock 12 Month Forecast
Average Price Target
$9.25
▲(1014.46% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Atara Biotherapeutics
―
X4 Pharmaceuticals
―
NRX Pharmaceuticals
―
CAMP4 Therapeutics Corporation
―
Best Analysts Covering HOWL
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-7.17%
reiterated a buy rating 27 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -7.17% per trade.
---